Figure 7.

Myeloid/lymphoid-specific marker expression of neurosphere-derived bone marrow cells and splenocytes. Analyses of representative animals 3 months post-transplant are shown (bone marrow transplant recipient (left); TSA/AzaC clone 1 recipient (right); two transplanted animals were analysed with similar results). Percentages of gated eGFP⁺ donor cells are plotted against lineage-specific staining. (A) eGFP⁺ donor cells in bone marrow were gated and plotted versus MAC1 and Gr1 staining; eGFP⁺ MAC1⁺ Gr1⁺ cells were gated and plotted versus CD19 staining. As a control, eGFP⁺ MAC1⁻ Gr1⁻ non-myeloid cells were plotted versus CD19 immunoreactivity (hatched line). (B) eGFP⁺ splenocytes were stained with anti-MAC1 and anti-Gr1 antibodies and counterstained with anti-CD3 antibodies. Gated eGFP⁺ MAC1⁻ Gr1⁻ cells were plotted versus CD3 staining (hatched line). (D) eGFP⁺ bone marrow cells were gated and plotted versus B220 and CD19 immunoreactivity; eGFP⁺ B220⁺ CD19⁺ cells were counterstained with anti-Gr1 antibodies. Gated eGFP⁺ B220⁻ CD19⁻ cells were plotted versus Gr1 staining (hatched line). Analyses of a representative animal 3 months post-transplant are shown.